Selected work showing the business challenge, what changed and the main result.
PROOF OF EXECUTION
Explore prior work in commercialization, program recovery, AI and governance. Each case shows the business challenge, what changed and the result.
GOVERNANCE, CONTROLS & EVIDENCE
FINANCIAL SERVICES
A buy-side asset manager evaluated how AI could improve client responses, preparedness and compliance while preserving operational accountability and pre-existing workflow investments.
Results:
97% first-pass accuracy rate
GO-TO-MARKET
HEALTHCARE & MEDICAL DEVICES
Advisory supported an orthopedic manufacturer’s board decisions on whether to scale, using buyer-specific economics, clinical workflow fit and commercial evidence under bundled-payment risk.
Results:
$1.86M modeled net impact
GOVERNANCE, CONTROLS & EVIDENCE
LEGAL / LITIGATION
Applied a custom case tagging framework for pinpointing evidence. The team reviewed approximately 100,000 mixed records against deposition deadlines while preserving privilege, source traceability and counsel control. Curation cut first-pass from 42 days to 2.5 days.
Results:
42 days → 2.5 days first-pass review
TRANSFORMATION & PROGRAM RECOVERY
HEALTHCARE & LIFE SCIENCES
PE-backed expansion needed faster registry launches, but each new program faced a proprietary EDC system path of more than $1M to build and $250K a year to support. InteliGems led an EDC and data redesign that informed the board’s platform decision, incorporating governed data design supporting 21 CFR Part 11 controls, pharmacovigilance safety feeds and specialist workflow. New registries avoided that cost structure, freeing scarce specialist capacity for new business.
Results & Targets:
$1M build + $250K/year cost path avoided per registry
Freed 6 staff-days/mo. specialist capacity
Target: 3d → 1d analytic prep
Target: 3+ mo → <1 mo form-change cycle
AI STRATEGY & OPERATING MODEL
OWNER-OPERATOR CASE STUDY | Strategic pivot
As meeting-intelligence competitors grew from roughly 10 to 80, the question was no longer what to ship. It was to stop funding and what to repurpose. As an owner-operator with capital at risk, the principal redirected capital, technical capacity, product development and GTM into private, governed AI for regulated enterprise work.
Results:
Hard stop
Owner capital at risk
3 AI platform generations
6–7 engineering FTE base
GOVERNANCE, CONTROLS & EVIDENCE
DEFENSE / DUAL-USE
High-volume export-control review of scientific research was consuming scarce specialist time on false alarms while dual-use risk and compliance rules kept changing. InteliGems designed and built an air-gapped, governed first-pass AI system with guardrails that scored compliance risk, assembled audit-traceable source evidence and escalated only cases that warranted specialist judgment. Specialists retained final determination; the reported evaluation cut noise and turnaround time.
Results:
False positives 30% → 3.2%
Screening 8h → 5m per proposal
AI STRATEGY & OPERATING MODEL
GROWTH · COMMERCIALIZATION
A proposed $1M+ license depended on roughly $300K in annual emergency-department avoidance value, leaving the investment case below the buyer’s hurdle. The advisory work rebuilt the case as four locally testable value pathways with explicit clinical, digital and financial owners. The result was a stronger buyer decision model that opened the door for deeper enterprise sales conversations.
Results:
Four buyer-testable economic pathways
2–3× expansion in modeled ROI
$1M–$5M+ potential modeled annual value
PROGRAM, PRODUCT & WORKFLOW LEADERSHIP
HEALTHCARE & LIFE SCIENCES
A real-world clinical evidence organization considered a universal tablet workflow to improve data timeliness and reduce manual work. InteliGems led field research at multiple sites and found ~25% of providers were unwilling to go fully digital. Facing provider disenrollment risk, the fieldwork showed that operating value and adoption friction sat in different workflow roles. InteliGems architected a 3-channel model to protect site retention, avoid custom software builds and reclaim specialist capacity.
Results:
72 specialist days/year reclaimed
$1M+ custom IT costs avoided
Three-channel workflow designed to protect clinical site retention
GO-TO-MARKET
MEDICAL DEVICES
A military-tested IV platform had 10 plausible civilian markets and no clear first buyer. The wrong beachhead risked wasted capital, retooling, and regulatory filing cost. InteliGems led customer discovery across those segments, evaluating workflows, unit economics and key opinion leader evidence and compressed validation from 90 days to 30 days. The sprint issued a No-Go on Urban EMS, prioritized large-animal field veterinary care against a $498.4M modeled TAM, and advanced a qualified buyer pipeline and master distribution terms. Leadership left with a board-ready advance-or-stop gate before further regulatory and capital commitments.
Results:
90 → 30 day validation cycle
Urban EMS: No-Go
$498.4M modeled field-veterinary TAM
Qualified buyer pipeline & master distribution terms
CATEGORY CREATION & ENTERPRISE SCALE · FOUNDER/CEO OPERATING RECORD
Physician cost and quality were difficult to measure and compare. Clinical standards were evolving, reliable data was fragmented, and national consumer interest in provider performance was nascent. The company had to develop credible measurement technology while creating the market for its products. This is a case study on creating a market category from scratch, fund raising from strategics, executing a complex SaaS pivot, and negotiating a challenging M&A exit.
As Founder & CEO, the principal developed proprietary measurement technology, including a granted U.S. patent; won national distribution through Cigna and Blue Cross Blue Shield channels; and transformed services into recurring SaaS. Five health plans became investors. The company (Med-Vantage) was acquired by IMS Health in 2011.
Results
25M+ reported covered-consumer reach
$1.1M → $2.1M SaaS licensing revenue (2007)
$14.4M Series A financing at $28M post-money valuation
GO-TO-MARKET
HEALTHCARE & LIFE SCIENCES
A health-risk analytics startup had validated genomics science but no repeatable B2B path. As fractional Chief Commercial Officer, the principal halted a capital-heavy consumer app direction, prioritized enterprise segments, and built the offer, pricing, contracting, and sales operating pieces needed to sell into healthcare and life insurance. Channel and enterprise pipeline discussions were advanced against a defined commercial system rather than another product feature cycle.
Results:
D2C thesis stopped
Three-tier packaging: $150K+ advisory, $25K+/mo license, $1M+/yr platform
Enterprise pipeline and channel paths advanced
TRANSFORMATION & PROGRAM RECOVERY
PUBLIC HEALTH / MEDICAID
Troubled Medicaid/MMIS programs across New Hampshire and Montana faced chronic schedule slips and contractual damages exposure. The principal reset governance, staffing, release discipline and executive reporting within a $1.5B state-healthcare portfolio, moving the programs out of reactive escalation and placing contractual damages and SLA exposure under formal recovery management. Rationalized EPMO resources and delivery staffing to address chronic delays and execution risks.
Results:
Two state programs reset under re-established governance
$30K/day contractual exposure placed under formal recovery management
GO-TO-MARKET
ENTERPRISE
A national health-plan account was stuck near $28M on traditional technology delivery, with limited growth beyond the existing service mix. With account P&L ownership, the principal secured executive sponsorship for broader mandates and expanded into higher-value product strategy, testing and business-process services, pairing new revenue with the capacity to deliver.
Results:
$28M → $51M in year one
$80M in year two
FRACTIONAL & INTERIM EXECUTIVE LEADERSHIP
ENTERPRISE OPERATIONS
A 1,100-person global account had eroding margin, unfavorable contract terms, late delivery, QA penalties, turnover and costly execution. With $90M P&L accountability, the principal led efforts to reset project cost estimation, delivery structure, quality controls and commercial terms so the account could meet commitments and restore profit.
Results:
Operating margin 6% → 44% over three years
SLA penalties $2.7M → $0
Top Account Award
GOVERNANCE, CONTROLS & EVIDENCE
PUBLIC SECTOR / JUDICIAL REVIEW
High-consequence quasi-judicial records require source-linked, inspectable evidence, not pattern matches. A forensic e-discovery review of a 58-page hearing-examiner ruling and related record linked claims to underlying documents, screened false positives and classified recurring bias mechanisms across seven categories. The findings were published to support the examination of viewpoint fairness, representation and potential judicial bias.
Results:
43 source-linked indicators across 7 categories of bias
Published